Trials / Terminated
TerminatedNCT02414984
Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab
Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (actual)
- Sponsor
- Janssen-Cilag, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe adherence to golimumab in Colombian participants with rheumatoid arthritis (RA) experiencing adequate treatment response, in a real-world clinical settings.
Detailed description
This is a multi-center (when more than one hospital or medical school team work on a medical research study), non-interventional, prospective cohort study that will enroll participants with RA in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for adherence to golimumab treatment for 24 months from study start (Week 0), and recommended follow up assessments will be every 3 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment. Participants' safety will be monitored throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Golimumab | This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months. |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
- First posted
- 2015-04-13
- Last updated
- 2017-02-13
Locations
5 sites across 1 country: Colombia
Source: ClinicalTrials.gov record NCT02414984. Inclusion in this directory is not an endorsement.